4D Molecular Therapeutics Ownership | Who Owns 4D Molecular Therapeutics?

Overview Forecast RevenueFinancials Chart

4D Molecular Therapeutics Ownership Summary

4D Molecular Therapeutics is owned by 85.49% institutional investors, 3.55% insiders, and 10.96% retail investors. Blackrock is the largest institutional shareholder, holding 9.94% of FDMT shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.32% of its assets in 4D Molecular Therapeutics shares.

FDMT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	4D Molecular Therapeutics	85.49%	3.55%	10.96%
Sector	Healthcare Stocks	35.56%	12.08%	52.36%
Industry	Biotech Stocks	35.43%	12.01%	52.56%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	4.90M	9.94%	$102.79M
Janus henderson group	5.25M	9.06%	$48.87M
Ra capital management	5.05M	8.72%	$47.01M
Goldman sachs group	4.21M	7.26%	$39.15M
Blackrock funding, inc. /de	4.55M	6.68%	$60.46M
Novo	3.65M	6.30%	$33.99M
Vanguard group	3.09M	5.51%	$23.20M
Bvf inc/il	2.88M	4.97%	$26.81M
State street	2.91M	4.28%	$38.72M
Armistice capital	2.00M	3.45%	$18.62M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Novo	3.65M	2.75%	$33.99M
Propel bio management	380.42K	2.26%	$3.58M
Bvf inc/il	2.88M	0.85%	$26.81M
Exome asset management	130.56K	0.63%	$1.22M
Persistent asset partners	145.59K	0.58%	$1.94M
Parkman healthcare partners	522.58K	0.50%	$4.87M
Ra capital management	5.05M	0.50%	$47.01M
Armistice capital	2.00M	0.33%	$18.62M
Rangeley capital	31.46K	0.28%	$292.94K
Principia wealth advisory	53.67K	0.25%	$402.51K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	4.90M	0.00%	612.35K
Janus henderson group	5.25M	0.02%	611.28K
Vanguard group	3.09M	0.00%	518.40K
Norges bank	500.82K	0.00%	500.82K
Nuveen	561.80K	0.00%	403.04K

Top Sellers

Holder	Shares	% Assets	Change
Viking global investors lp	-	-	-2.93M
Bvf inc/il	2.88M	0.85%	-1.75M
Point72 asset management	-	-	-1.54M
Braidwell lp	-	-	-1.23M
Casdin capital	-	-	-1.15M

New Positions

Holder	Shares	% Assets	Change	Value
Norges bank	500.82K	0.00%	500.82K	$2.79M
Propel bio management	380.42K	2.26%	380.42K	$3.58M
Vanguard fiduciary trust	269.30K	0.00%	269.30K	$2.51M
Persistent asset partners	145.59K	0.58%	145.59K	$1.94M
Exome asset management	130.56K	0.63%	130.56K	$1.22M

Sold Out

Holder	Change
Innealta capital	-4.00
Nelson, van denburg & campbell wealth management group	-8.00
Root financial partners	-11.00
Sound income strategies	-25.00
Allspring global investments	-27.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	151	-2.58%	49,527,045	-7.29%	85	0.94%	68	-21.84%	46	24.32%
Dec 31, 2025	40	-70.59%	5,592,450	-85.86%	9	0.20%	21	-69.12%	10	-77.78%
Sep 30, 2025	39	-65.49%	6,758,953	-80.69%	12	0.31%	21	-62.50%	11	-69.44%
Jun 30, 2025	120	-4.00%	40,390,122	-6.26%	72	1.21%	58	23.40%	39	-35.00%
Mar 31, 2025	125	-14.38%	43,088,441	-8.05%	77	1.09%	47	-43.37%	60	36.36%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	1.54M	3.32%	-
Vanguard Total Stock Mkt Idx Inv	1.59M	3.04%	-65.87K
Vanguard Morn Total Stk Mkt Idx Investor	1.59M	3.04%	-65.87K
State Street® SPDR® S&P® Biotech ETF	1.58M	3.03%	3.64K
iShares Russell 2000 ETF	1.17M	2.24%	-20.83K
SPDR® S&P Biotech ETF	986.40K	2.13%	14.03K
Janus Henderson Hrzn Biotec E2 USD	904.51K	1.73%	-79.83K
Janus Henderson Gbl Life Sciences Divers	851.19K	1.67%	851.19K
Janus Henderson Global Life Sciences D	840.95K	1.61%	-2.80K
Polar Capital Healthcare Opports Inc	790.16K	1.52%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Aug 04, 2026	Kirn David	See Remarks	Sell	$274.60K
Aug 03, 2026	Kirn David	See Remarks	Sell	$124.72K
Jul 10, 2026	Kirn David	See Remarks	Sell	$183.56K
Jul 09, 2026	Kirn David	See Remarks	Sell	$548.18K
Jul 10, 2026	Kirn David	See Remarks	Sell	$5.67K

Insider Transactions Trends

Date	Buy	Sell
2026 Q3	-	5
2026 Q2	-	4
2026 Q1	-	2
2025 Q4	-	7
2025 Q3	-	1

FDMT Ownership FAQ

Who Owns 4D Molecular Therapeutics?

4D Molecular Therapeutics shareholders are primarily institutional investors at 85.49%, followed by 3.55% insiders and 10.96% retail investors. The average institutional ownership in 4D Molecular Therapeutics's industry, Biotech Stocks , is 35.43%, which 4D Molecular Therapeutics exceeds.

Who owns the most shares of 4D Molecular Therapeutics?

4D Molecular Therapeutics’s largest shareholders are Blackrock (4.9M shares, 9.94%), Janus henderson group (5.25M shares, 9.06%), and Ra capital management (5.05M shares, 8.72%). Together, they hold 27.71% of 4D Molecular Therapeutics’s total shares outstanding.

Does Blackrock own 4D Molecular Therapeutics?

Yes, BlackRock owns 9.94% of 4D Molecular Therapeutics, totaling 4.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 102.79M$. In the last quarter, BlackRock increased its holdings by 612.35K shares, a 14.29% change.

Who is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested?

Novo is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.75% of its assets in 3.65M 4D Molecular Therapeutics shares, valued at 33.99M$.

Who is the top mutual fund holder of 4D Molecular Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of 4D Molecular Therapeutics shares, with 3.32% of its total shares outstanding invested in 1.54M 4D Molecular Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools